Jane de Lartigue, PhD

Articles

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

NRG1 Fusions Hold Promise as Pan-tumor Target

November 17th 2020

The identification of chromosomal rearrangements that result in oncogenic gene fusions ushered in the era of molecularly targeted therapies in oncology.

NEDD8 Emerges as a Novel Target in Hematologic Malignancies

October 8th 2020

Investigators are developing a new way to target a key oncogenic mechanism that may prove to be an effective anticancer strategy, particularly against hematologic malignancies.

Interest Builds for Targeting TIGIT Checkpoint

September 15th 2020

TIGIT, an inhibitory immune checkpoint that plays a central role in limiting antitumor responses, is attracting robust interest in the research community as a novel target for combination therapies across a range of cancer types, particularly solid tumors.

New Era for Targeting HER2 Beckons in Breast Cancer and Beyond

September 3rd 2020

Precision medicine advancements are opening a new chapter in the development of anticancer therapies that target the HER2 pathway, resulting in 3 approvals for breast cancer in less than a year and raising hopes for attacking other cancer types.

Fresh Approaches May Be Key to Unlocking OX40 Checkpoint

August 21st 2020

Considerable efforts have focused on developing agonists of costimulatory receptors, including OX40.

HRD Testing Heralds a New Biomarker, but Questions Linger

August 5th 2020

Homologous recombination, one of the major mechanisms of defective DNA repair, has emerged as a bona fide therapeutic target, yet its optimal use as a biomarker for patient selection remains a clouded scientific question.

CLR 131 Leads a New Generation of Lipid-Based Cancer Drug Delivery Systems

July 19th 2020

A novel compound that uses abundant lipids in cancer cell membranes to deliver a radioisotope to the tumor environment shows early signs of efficacy in a range of B-cell malignancies.

New Strategies for Targeting CD38 in Multiple Myeloma Take Root

June 26th 2020

During the past 5 years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma.

A New Generation of Drugs Targeting PD-1/PD-L1 Takes Shape in Oncology

June 8th 2020

Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.

x